Literature DB >> 4011126

Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy.

I S Benarroch, M Brodsky, A Rubinstein, C Viggiano, E A Salama.   

Abstract

This double-blind randomized trial was carried out on 37 patients with diabetic retinopathy and blood hyperviscosity. 19 patients received calcium dobesilate in capsules of 500 mg 3 times daily for 3 months and 18 patients took 3 placebo capsules daily during the same period. Calcium dobesilate was found to reduce whole-blood viscosity in a statistically significant manner which was accompanied by a diminution of the albumin/globulin ratio and a significant reduction of fibrinogen and cholesterol levels. A statistically significant diminution of capillary fragility was also observed in the calcium dobesilate-treated group. These results indicate that calcium dobesilate, by restoring the integrity of the microvessels, and by lowering blood viscosity, could act favorably on the evolution of diabetic retinopathy.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4011126     DOI： 10.1159/000265364

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN： 0030-3747            Impact factor:   2.892


  9 in total

1.  Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy.

Authors:  E B Leite; M C Mota; J R de Abreu; J G Cunha-Vaz
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

2.  Pharmacokinetics of calcium dobesilate in beagle dogs after a single administration.

Authors:  C T Plessas; P Karayannakos; S T Plessas; A Costakis; I Donta; G Skalkeas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

3.  Pharmacokinetics of calcium dobesilate in beagle dogs after repeated administration.

Authors:  C T Plessas; P Karayannakos; S T Plessas; A Costakis; I Donta; G Skalkeas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

4.  Effect of calcium dobesilate on retrobulbar blood flow and choroidal thickness in patients with non-proliferative diabetic retinopathy.

Authors:  Hossein Ashraf; Mehrzad Lotfi; Maryam Akbari; Hamidreza Jahanbani-Ardakani; Morteza Ghaffari; Mohammad Reza Khalili
Journal:  Int Ophthalmol       Date:  2021-08-02       Impact factor: 2.031

Review 5.  Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.

Authors:  Rafael Simó; Stefania Ballarini; José Cunha-Vaz; Linong Ji; Hermann Haller; Paul Zimmet; Tien Y Wong
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 6.  Update on the Effects of Antioxidants on Diabetic Retinopathy: In Vitro Experiments, Animal Studies and Clinical Trials.

Authors:  Jose Javier Garcia-Medina; Elena Rubio-Velazquez; Elisa Foulquie-Moreno; Ricardo P Casaroli-Marano; Maria Dolores Pinazo-Duran; Vicente Zanon-Moreno; Monica Del-Rio-Vellosillo
Journal:  Antioxidants (Basel)       Date:  2020-06-26

Review 7.  Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.

Authors:  Armando Mansilha; Joel Sousa
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

8.  Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy.

Authors:  Alireza Javadzadeh; Amir Ghorbanihaghjo; Farzad Hami Adl; Dima Andalib; Hassan Khojasteh-Jafari; Kamyar Ghabili
Journal:  Mol Vis       Date:  2013-01-10       Impact factor: 2.367

9.  Therapeutic effects of calcium dobesilate on diabetic nephropathy mediated through reduction of expression of PAI-1.

Authors:  Xiaoqian Zhang
Journal:  Exp Ther Med       Date:  2012-10-19       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.